Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy

Recruiting now · Not applicable

Conditions studied: Helicobacter Pylori Infection

In brief

(1) To compare the efficacy and safety of a 14-day bismuth-amoxicillin-vonoprazan triple therapy versus a 14-day bismuth-based quadruple therapy as first-line treatments for H. pylori infection, and (2) To investigate the influence of H. pylori antibiotic resistance, along with host CYP3A4, CYP2C19, and IL-1B -511 genotypes, on the eradication efficacy of H. pylori therapies.

Key facts

Study ID

NCT07358130

Run by

Kaohsiung Medical University

People needed

552

Starts

2025-10-21

Expected to finish

2027-12-31

Last updated by the study team

2026-01-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with Helicobacter pylori infection

You may not qualify if…

• Subjects with known hypersensitivity to the study drug.
• Subjects with a history of gastric surgery.
• Subjects with severe liver cirrhosis or uremia.
• Subjects with a history of malignancy within the past five years.
• Pregnant or breastfeeding women.
• Subjects currently receiving treatment with atazanavir sulfate or rilpivirine hydrochloride.

Where it is running

• Kaohsiung Medical University Hospital — Kaohsiung City, Taiwan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.